Pythia BioSciences and Lexogen Partner to Unify Multi-Omics Data Curation and Analytics with Bulk and Single-Cell RNA Sequencing

SAN DIEGO, CA, UNITED STATES, July 20, 2026 ––  Pythia Biosciences and Lexogen recently announced a strategic partnership to empower researchers with deeper biological insights by combining Lexogen’s expertise in RNA sequencing and library preparation with Pythia’s multi-omics data curation and analytics capabilities. Through this collaboration, Pythia will offer Lexogen’s wet-lab capabilities via direct sales and as a core component of its newly launched expanded data ecosystem focused on maximising proprietary data generation and cohort building through a global network of biobank sample providers and multi-omics wet-lab partners. Together, Lexogen and Pythia are accelerating the drug discovery and development pipeline, enabling biopharma teams to rapidly transform complex biological samples into actionable therapeutic insights.

While high-quality public datasets from Pythia are valuable for drug discovery, finding cohorts that match specific therapeutic questions is notoriously difficult. Public repositories are often limited by disease representation, sparse treatment metadata, and small patient sizes. The Pythia-Lexogen partnership directly eliminates these hurdles, unifying advanced analytics and standardized data curation workflows with Lexogen's streamlined, custom wet-lab data generation.

The integrated Pythia ecosystem accelerates drug discovery by guiding researchers through three distinct phases of data exploration and experimental design. First, teams leverage Pythiomics to access fully curated, high-quality, and harmonized multi-omic public datasets. To fill specific data gaps, researchers can query the Pythia Data Forge, an incubator repository housing hundreds of thousands of searchable datasets that can be manually quality-controlled and finalized in under a week to expand the active cohort. By blending these comprehensive, criteria-matched datasets, scientists can pinpoint the critical biological signals needed to accurately inform future experiments. Finally, through the Pythia Data Universe, teams can source optimized biobank samples and connect with premier multi-omics wet-lab providers, allowing them to precisely execute custom bulk and single-cell RNA-seq (scRNA-seq) experiments powered by Lexogen.

“Lexogen’s twenty years of proven data excellence and their ability to execute on projects exceeding 100,000 samples make them the ideal partner for Pythia,” stated Tristan Gill, CEO of Pythia BioSciences. “Together, we are empowering the scientific community to accelerate drug discovery and deliver life-changing therapies to the patients who need them most.”

Stéphane Barges, CEO of Lexogen, also added: “By combining our sequencing expertise with Pythia's rigorous data harmonization and curation pipeline, we hope to expand both the quantity and diversity of high-quality RNA-seq datasets available to researchers. Ultimately, this will enable more data-driven research with broader biological insights and accelerate more discoveries.”

For more information about the collaboration, please contact Pythia Biosciences at www.pythiabio.com or Lexogen at: https://www.lexogen.com/.

------------------

About Pythia Biosciences

Pythia BioSciences is a leading provider of multi-omics software, curated content, and advanced bioinformatics services designed to streamline data-driven drug discovery. By combining Pythiomics, a meticulously harmonized multi-omic database, with the C-DIAM Multi-Omics Studio analytical platform and advanced API for cross-database queries and programmatic analysis, Pythia helps scientists get the accurate biological insights they need to accelerate drug discovery and development. The company's unique technology ecosystem empowers biopharmaceutical teams to rapidly turn disparate biological datasets into actionable therapeutic insights. To learn more, visit www.pythiabio.com.

About Lexogen

Lexogen is an Austrian biotechnology company specializing in RNA sequencing and transcriptomics. With nearly 20 years of expertise, the company develops tools and provides scalable sequencing services for both single-cell and bulk RNA applications, supporting virtually any sample type used in transcriptomics research. Widely recognized as the inventor of 3′ mRNA sequencing, Lexogen has demonstrated the ability to process more than 100,000 samples while maintaining rigorous quality standards. This scalability complements Pythia's expanding data ecosystem, enabling the partnership to support large-scale transcriptomics projects from sample sequencing to analysis-ready datasets. Lexogen operates under ISO 13485 and GCLP.